
Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from the 52-week Phase 2b extension study
W. Carr, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, M. Wells, A. Zharkov, S. Hugot, A.M. Giménez-Arnau